References
1. Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to
characterize use of Spice products (synthetic cannabinoids). Drug
Alcohol Depend 2012;120(1-3):238-41.
2. Varga K, Wagner JA, Bridgen DT, Kunos GJTFj. Platelet‐and
macrophage‐derived endogenous cannabinoids are involved in
endotoxin‐induced hypotension. 1998;12(11):1035-1044.
3. Pacher P, Bátkai S, Kunos GJPr. The endocannabinoid system as an
emerging target of pharmacotherapy. 2006;58(3):389-462.
4. Ashton JC, Smith PFJCvp. Cannabinoids and cardiovascular disease: the
outlook for clinical treatments. 2007;5(3):175-184.
5. Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Bátkai S, Kunos
GJH. Modulation of the endocannabinoid system in cardiovascular disease:
therapeutic potential and limitations. 2008;52(4):601-607.
6. Goyal H, Awad HH, Ghali JKJJotd. Role of cannabis in cardiovascular
disorders. 2017;9(7):2079.
7. Pacher P, Steffens S. The emerging role of the endocannabinoid system
in cardiovascular disease. 2009. Springer. p 63-77.
8. Nelson MA. MECHANISMS OF SYNTHETIC CANNABINOIDS ON CARDIOVASCULAR
HEALTH. 2021.
9. Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated
with use of the synthetic cannabinoid K2. Pediatrics
2011;128(6):e1622-7.
10. Young AC, Schwarz E, Medina G, Obafemi A, Feng SY, Kane C,
Kleinschmidt K. Cardiotoxicity associated with the synthetic
cannabinoid, K9, with laboratory confirmation. Am J Emerg Med
2012;30(7):1320.e5-7.
11. Su MK, Seely KA, Moran JH, Hoffman RS. Metabolism of classical
cannabinoids and the synthetic cannabinoid JWH-018. Clin Pharmacol Ther
2015;97(6):562-4.
12. Cooper ZD. Adverse Effects of Synthetic Cannabinoids: Management of
Acute Toxicity and Withdrawal. Curr Psychiatry Rep 2016;18(5):52.
13. Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid
System: Signaling and Function in the Central Nervous System.
International journal of molecular sciences 2018;19(3):833.
14. Bonz A, Laser M, Küllmer S, Kniesch S, Babin-Ebell J, Popp V, Ertl
G, Wagner JA. Cannabinoids acting on CB1 receptors decrease contractile
performance in human atrial muscle. J Cardiovasc Pharmacol
2003;41(4):657-64.
15. Rajesh M, Bátkai S, Kechrid M, Mukhopadhyay P, Lee WS, Horváth B,
Holovac E, Cinar R, Liaudet L, Mackie K and others. Cannabinoid 1
receptor promotes cardiac dysfunction, oxidative stress, inflammation,
and fibrosis in diabetic cardiomyopathy. Diabetes 2012;61(3):716-27.
16. Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K.
Detection of an endogenous cannabimimetic molecule,
2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human
vascular cells: is 2-arachidonoylglycerol a possible vasomodulator?
Biochem Biophys Res Commun 1998;243(3):838-43.
17. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P,
Bouaboula M, Shire D, Le Fur G, Casellas P. Expression of central and
peripheral cannabinoid receptors in human immune tissues and leukocyte
subpopulations. Eur J Biochem 1995;232(1):54-61.
18. Niederhoffer N, Schmid K, Szabo B. The peripheral sympathetic
nervous system is the major target of cannabinoids in eliciting
cardiovascular depression. Naunyn Schmiedebergs Arch Pharmacol
2003;367(5):434-43.
19. Czeisler M, Lane RI, Petrosky E, Wiley JF, Christensen A, Njai R,
Weaver MD, Robbins R, Facer-Childs ER, Barger LK and others. Mental
Health, Substance Use, and Suicidal Ideation During the COVID-19
Pandemic - United States, June 24-30, 2020. MMWR Morb Mortal Wkly Rep
2020;69(32):1049-1057.
20. Chung EY, Cha HJ, Min HK, Yun J. Pharmacology and adverse effects of
new psychoactive substances: synthetic cannabinoid receptor agonists.
Arch Pharm Res 2021;44(4):402-413.
21. Tai S, Fantegrossi WE. Pharmacological and Toxicological Effects of
Synthetic Cannabinoids and Their Metabolites. Current topics in
behavioral neurosciences 2017;32:249-262.
22. Schoeder CT, Hess C, Madea B, Meiler J, Müller CE. Pharmacological
evaluation of new constituents of “Spice”: synthetic cannabinoids
based on indole, indazole, benzimidazole and carbazole scaffolds.
Forensic Toxicology 2018;36(2):385-403.
23. Eid BG. Cannabinoids for Treating Cardiovascular Disorders: Putting
Together a Complex Puzzle. Journal of microscopy and ultrastructure
2018;6(4):171-176.
24. Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson
SM, Beinat C, Buchanan AS, Hibbs DE, Glass M and others. Effects of
bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018,
AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chem
Neurosci 2015;6(8):1445-58.
25. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, Group
NCRRGW. Animal research: reporting in vivo experiments: the ARRIVE
guidelines. British journal of pharmacology 2010;160(7):1577-1579.
26. Walker MJA, Curtis M, Hearse DJ, Campbell RWF, Riva E, Janse M,
Yellon DM, Cobbe SM, Coker SJ, Harness JB and others. The Lambeth
Conventions: Guidelines for the study of arrhythmias in ischaemia
infarction, and reperfusion. Cardiovascular research 1988;22:447-55.
27. Bentli R, Parlakpinar H, Polat A, Samdanci E, Sarihan ME, Sagir M.
Molsidomine prevents cisplatin-induced hepatotoxicity. Arch Med Res
2013;44(7):521-8.
28. Poklis JL, Amira D, Wise LE, Wiebelhaus JM, Haggerty BJ, Lichtman
AH, Poklis A. Determination of
naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in mouse blood
and tissue after inhalation exposure to ’buzz’ smoke by HPLC/MS/MS.
Biomed Chromatogr 2012;26(11):1393-8.
29. Poklis JL, Amira D, Wise LE, Wiebelhaus JM, Haggerty BJ, Poklis A.
Detection and disposition of JWH-018 and JWH-073 in mice after exposure
to ”Magic Gold” smoke. Forensic science international
2012;220(1-3):91-96.
30. O’Sullivan SE. Endocannabinoids and the Cardiovascular System in
Health and Disease. Handb Exp Pharmacol 2015;231:393-422.
31. Ozturk HM, Yetkin E, Ozturk S. Synthetic Cannabinoids and Cardiac
Arrhythmia Risk: Review of the Literature. Cardiovasc Toxicol
2019;19(3):191-197.
32. Von Der Haar J, Talebi S, Ghobadi F, Singh S, Chirurgi R, Rajeswari
P, Kalantari H, Hassen GW. Synthetic Cannabinoids and Their Effects on
the Cardiovascular System. J Emerg Med 2016;50(2):258-62.
33. Parlakpinar H, Celbis O, Ozhan O, Petekkaya S, Samdanci E, Ermis N,
Koparir P, Soylu O, Acet A. Cardiovascular effects of JWH-018 from
synthetic cannabinoids. 2016.
34. Lake KD, Compton DR, Varga K, Martin BR, Kunos G.
Cannabinoid-induced hypotension and bradycardia in rats mediated by
CB1-like cannabinoid receptors. J Pharmacol Exp Ther 1997;281(3):1030-7.
35. Hillard CJ. Endocannabinoids and vascular function. J Pharmacol Exp
Ther 2000;294(1):27-32.
36. Ford WR, Honan SA, White R, Hiley CR. Evidence of a novel site
mediating anandamide-induced negative inotropic and coronary
vasodilatator responses in rat isolated hearts. Br J Pharmacol
2002;135(5):1191-8.
37. Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G. Mechanism of the
hypotensive action of anandamide in anesthetized rats. Hypertension
1996;28(4):682-6.
38. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Böhme
GA, Imperato A, Pedrazzini T, Roques BP and others. Unresponsiveness to
cannabinoids and reduced addictive effects of opiates in CB1 receptor
knockout mice. Science 1999;283(5400):401-4.
39. Bátkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White
J, Offertáler L, Mackie K, Rudd MA, Bukoski RD and others.
Endocannabinoids acting at cannabinoid-1 receptors regulate
cardiovascular function in hypertension. Circulation
2004;110(14):1996-2002.
40. Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunos G. Inhibition
of exocytotic noradrenaline release by presynaptic cannabinoid CB1
receptors on peripheral sympathetic nerves. Br J Pharmacol
1996;118(8):2023-8.
41. Malinowska B, Godlewski G, Bucher B, Schlicker E. Cannabinoid CB1
receptor-mediated inhibition of the neurogenic vasopressor response in
the pithed rat. Naunyn Schmiedebergs Arch Pharmacol 1997;356(2):197-202.
42. Wagner JA, Járai Z, Bátkai S, Kunos G. Hemodynamic effects of
cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid
CB(1) receptors. Eur J Pharmacol 2001;423(2-3):203-10.
43. Vidrio H, Sánchez-Salvatori MA, Medina M. Cardiovascular effects of
(-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl in rats. J
Cardiovasc Pharmacol 1996;28(2):332-6.
44. Pacher P, Bátkai S, Kunos G. Haemodynamic profile and responsiveness
to anandamide of TRPV1 receptor knock-out mice. J Physiol 2004;558(Pt
2):647-57.
45. Al Kury LT, Voitychuk OI, Yang KH, Thayyullathil FT, Doroshenko P,
Ramez AM, Shuba YM, Galadari S, Howarth FC, Oz M. Effects of the
endogenous cannabinoid anandamide on voltage-dependent sodium and
calcium channels in rat ventricular myocytes. Br J Pharmacol
2014;171(14):3485-98.
46. Li Q, Ma HJ, Zhang H, Qi Z, Guan Y, Zhang Y. Electrophysiological
effects of anandamide on rat myocardium. Br J Pharmacol
2009;158(8):2022-9.
47. Yun J, Yoon KS, Lee TH, Lee H, Gu SM, Song YJ, Cha HJ, Han KM, Seo
H, Shin J and others. Synthetic cannabinoid, JWH-030, induces QT
prolongation through hERG channel inhibition. Toxicol Res (Camb)
2016;5(6):1663-1671.
48. Hancox JC, Kalk NJ, Henderson G. Synthetic cannabinoids and
potential cardiac arrhythmia risk: an important message for drug users.
Ther Adv Drug Saf 2020;11:2042098620913416.
49. McKeever RG, Vearrier D, Jacobs D, LaSala G, Okaneku J, Greenberg
MI. K2–not the spice of life; synthetic cannabinoids and ST elevation
myocardial infarction: a case report. J Med Toxicol 2015;11(1):129-31.
50. Heath TS, Burroughs Z, Thompson AJ, Tecklenburg FW. Acute
intoxication caused by a synthetic cannabinoid in two adolescents. J
Pediatr Pharmacol Ther 2012;17(2):177-81.
51. Paul ABM, Simms L, Amini S, Paul AE. Teens and Spice: A Review of
Adolescent Fatalities Associated with Synthetic Cannabinoid Use. J
Forensic Sci 2018;63(4):1321-1324.
52. Di Marzo V, Matias I. Endocannabinoid control of food intake and
energy balance. Nat Neurosci 2005;8(5):585-9.
53. Carai MA, Colombo G, Maccioni P, Gessa GL. Efficacy of rimonabant
and other cannabinoid CB1 receptor antagonists in reducing food intake
and body weight: preclinical and clinical data. CNS Drug Rev
2006;12(2):91-9.
54. Cooper ZDJCpr. Adverse effects of synthetic cannabinoids: management
of acute toxicity and withdrawal. 2016;18(5):1-10.
55. Dalton VS, Wang H, Zavitsanou K. HU210-induced downregulation in
cannabinoid CB1 receptor binding strongly correlates with body weight
loss in the adult rat. Neurochem Res 2009;34(7):1343-53.
56. Ashino T, Hakukawa K, Itoh Y, Numazawa S. Inhibitory effect of
synthetic cannabinoids on CYP1A activity in mouse liver microsomes. J
Toxicol Sci 2014;39(6):815-20.
57. Chimalakonda KC, James LP, Radominska-Pandya A, Moran JH.
Sulfaphenazole and α-naphthoflavone attenuate the metabolism of the
synthetic cannabinoids JWH-018 and AM2201 found in K2/spice. Drug Metab
Lett 2013;7(1):34-8.
58. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE,
Prather PL. Phase I hydroxylated metabolites of the K2 synthetic
cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor
affinity and activity. PLoS One 2011;6(7):e21917.
59. Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL. Human
metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high
affinity and act as potent agonists at cannabinoid type-2 receptors.
Toxicol Appl Pharmacol 2013;269(2):100-8.
60. Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y. Chemical analysis of
synthetic cannabinoids as designer drugs in herbal products. Forensic
Sci Int 2010;198(1-3):31-8.
61. Wintermeyer A, Möller I, Thevis M, Jübner M, Beike J, Rothschild MA,
Bender K. In vitro phase I metabolism of the synthetic cannabimimetic
JWH-018. Anal Bioanal Chem 2010;398(5):2141-53.
62. White CM. The Pharmacologic and Clinical Effects of Illicit
Synthetic Cannabinoids. J Clin Pharmacol 2017;57(3):297-304.
63. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S,
Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and
clinical implications. Drug Alcohol Depend 2014;144:12-41.